BioCentury
ARTICLE | Financial News

May 20 Financial Quick Takes: Schrödinger tops off E round; plus Mabpharm IPO update, DNA Script, ADMA Biologics, Storm

May 20, 2019 2:42 PM UTC

Schrödinger brings E round to $110M
Computational physics company Schrödinger LLC (New York, N.Y.) closed the second tranche of its total $110 million series E round to support development of its technology platform and expand its discovery pipeline. New investors participating include Invus, Pavilion Capital, Tubus Management, Laurion Capital Management and a fund controlled by Michael Antonov. The Bill and Melinda Gates Foundation Trust and the corporate venture fund of WuXi AppTec Co. Ltd. (Shanghai:603259) led the first tranche of $85 million (see “Schrödinger Raises $85 Million in Series E Round”).

Mabpharm sets terms for Hong Kong IPO
Mabpharm Ltd. (Taizhou, China) would be valued at HK7.1 billion ($906.4 million) if it prices its Hong Kong IPO at the midpoint of its proposed range. The biosimilars company proposed to sell 783.6 million shares at HK1.50-HK1.95 on the Hong Kong stock exchange; at the HK1.73 midpoint, Mabpharm would raise HK1.4 billion ($172.2 million) (see "Biosimilars Company Mabpharm Sets Sights on Hong Kong IPO")...